Skip to main content

Amgen’s cancer-drug pipeline looks promising despite FDA setback, analysts say

Strong oncology, obesity, and cardiovascular drug candidates behind rating upgrade
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.